Cellphire Therapeutics
PrivateLast Round
Series A
Apr 2, 2021
Total Funding Raised
$104.25M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Cellphire Therapeutics is a clinical-stage biotechnology company that develops next-generation platelet-derived therapeutics to treat hemorrhaging.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials, Defense Tech
Business Model
B2G
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cellphire Therapeutics Comparables
Compare Cellphire Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Haima Therapeutics | 81% | |
| Cayuga Biotech | 73% | |
| Velico Medical | 72% |
Cellphire Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 2, 2021 | ||||
| Grant | Jan 15, 2020 | ||||
| Early Funding | Jun 5, 2017 | ||||
| VC Round | Jun 10, 2014 |
Cellphire Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TEDCO | VC Round |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| U.S. Army Medical Research Acquisition Activity | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 47% MoM.
- Aug 17, 2026
Open roles doubled to 10, representing 21% of headcount.
Recent news
Latest coverage and updates
- hiresSep 22, 2026
Cellphire, Inc. hires humberto Moran as Vice President of Manufacturing Technical Operations.
- hiresSep 22, 2026
Cellphire, Inc. hires Moran.
Cellphire Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cellphire Therapeutics's valuation, stock price, and market status.
Is Cellphire Therapeutics a public or private company?
Cellphire Therapeutics is a private company.
What is the current stock price of Cellphire Therapeutics?
Cellphire Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Cellphire Therapeutics worth (valuation)?
Valuation information for Cellphire Therapeutics is not publicly available.
Can I buy Cellphire Therapeutics stock?
Cellphire Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Cellphire Therapeutics's last funding round?
Cellphire Therapeutics's most recent funding round was Series A on April 2, 2021.
Who are the main investors in Cellphire Therapeutics?
Key investors in Cellphire Therapeutics include TEDCO, Public Health Emergency Medical Countermeasures Enterprise, U.S. Army Medical Research Acquisition Activity.
Will Cellphire Therapeutics IPO soon?
No public IPO plans have been announced for Cellphire Therapeutics.
How can I track Cellphire Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cellphire Therapeutics's secondary market activity and sign up for updates.